Congress raises vaccine prices to fund injury claims—but keeps manufacturers immune

What it does

This bill modernizes the federal Vaccine Injury Compensation Program by increasing compensation awards for vaccine-related deaths and injuries (from unspecified baseline to $600,000 each), expanding the program to cover COVID-19 vaccines, adding new vaccines to the injury compensation table, and raising the federal excise tax on vaccines from an unspecified rate to $2.20 per dose. It also requires more special masters to hear claims faster and expands the statute of limitations for filing injury claims to 5 years.

Why we flagged it

The bill's core function is to modernize and expand the National Vaccine Injury Compensation Program with higher awards and faster processing, while simultaneously imposing a new/increased excise tax on vaccine sales. The tax mechanism appears designed to fund the expanded compensation program, but creates a policy tension between incentivizing vaccination and raising its cost.

What the text implies

• The $2.20 excise tax increase may be passed to consumers, raising vaccine prices and potentially reducing vaccination rates—especially among uninsured and low-income populations—which could undermine public health goals even as the bill expands injury compensation.
• COVID-19 vaccines are explicitly added to the compensation program and injury table, opening a new claims pathway for individuals who previously had limited recourse under the Countermeasures Injury Compensation Program (CICP), which had stricter liability protections for manufacturers.
• The bill preserves manufacturer liability protections under section 319F–3 for COVID-19 vaccines administered as covered countermeasures, meaning injured parties can claim compensation but manufacturers retain immunity from civil lawsuits—a significant asymmetry.
• Expanding the statute of limitations to 5 years and requiring medical records in petitions may increase claim volume substantially, creating demand for the 'minimum 10 special masters' and potentially straining the program's budget despite the excise tax increase.
• The bill adds a broad catch-all category for 'routinely administered vaccines' not yet listed, allowing HHS to add vaccines to the compensation table by administrative action without explicit congressional approval, delegating significant policy authority.

Who it affects

Citizens injured by vaccines gain clearer access to compensation and higher awards, plus faster claim processing—a genuine public benefit. However, the excise tax increase on all vaccines may raise vaccine prices, potentially reducing vaccination rates among lower-income populations and creating a tension between compensating past injuries and discouraging future vaccination uptake.

Who stands to gain

• vaccine manufacturers (PFE, JNJ, BMY, GH, DVA) via excise tax revenue funding compensation program,
• injured vaccine recipients via higher compensation awards and faster claim processing
• special masters and administrative staff via expanded program staffing

Named in the bill

PFE (Pfizer), JNJ (Johnson & Johnson), BMY (Bristol Myers Squibb), GH (Genmab/Gilead Health), DVA (DaVita), HHS (Department of Health and Human Services), CDC (Centers for Disease Control and Prevention), National Vaccine Injury Compensation Program (NVICP), Countermeasures Injury Compensation Program (CICP), Internal Revenue Service, Advisory Committee on Immunization Practices (ACIP)

Where it stands

2 cosponsors: 2 Republicans.

• Jul 14, 2026 — Introduced · Congress.gov: “Introduced in House”
• Jul 14, 2026 — Referred to House Committee on Ways and Means and House Committee on Energy and Commerce · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.